Eugene A. Bauer

Biography

Dr. Eugene Bauer has been a member of Medgenics Board since March 2001. He is the Lucy Becker Professor (Emeritus) in the School of Medicine at Stanford University, having served as Vice President for Medical Affairs (1997-2001) and Dean of the School of Medicine (1995-2001) at Stanford University and as Chair of the Department of Dermatology at the Stanford University School of Medicine from 1988-1995. Currently, Dr. Bauer is Founder, Chief Medical Officer and a member of the Board of Directors of Dermira, Inc. (Nasdaq: DERM). Dr. Bauer is also immediate-past President & Chief Medical Officer of Peplin, Inc., a position he held from 2008 to December 2009, when Peplin was acquired by LEO Pharma. Prior to Peplin, he was founding Chief Executive Officer of Neosil, Inc., also a development stage pharmaceutical company that was acquired by Peplin, Inc., in 2008. He was a co-founder and emeritus member of the board of directors of Connetics Corporation (Nasdaq: CNCT), a publicly traded, dermatology-focused therapeutics company which was acquired by Steifel Laboratories and later sold to GlaxoSmithKline, Inc. For 25 years Dr. Bauer was an NIH-funded investigator and served on review groups at the National Institutes of Health, including as a member of the Advisory Council for the National Institute of Arthritis and Musculoskeletal and Skin Disease. He also served as a member of the Board of Scientific Counselors of the Division of Cancer Biology, Diagnosis and Centers of the National Cancer Institute. Dr. Bauer received an M.D. from Northwestern University. He has been elected to several honorific societies, including the National Academy of Medicine. He has published more than 200 scientific articles and book chapters and has been honored by the Society for Investigative Dermatology (the Montagna Award and the Stephen Rothman Award), by the American Academy of Dermatology (the Sulzberger Award), and by Northwestern University (Alumni Merit Award and FSM Distinguished Alumnus Award). 

Research Interest

Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases.